Published in Psychopharmacology (Berl) on January 01, 1986
Effect of lithium maintenance treatment on hypothalamic pituitary gonadal axis in bipolar men. J Psychiatry Neurosci (1996) 0.78
Depression resistant to tricyclic antidepressants. BMJ (1988) 0.75
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Defining substance use disorders: do we really need more than heavy use? Alcohol Alcohol (2013) 3.72
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Does the brain noradrenaline network mediate the effects of the CO2 challenge? J Psychopharmacol (2003) 2.81
Relapse of depression after rapid depletion of tryptophan. Lancet (1997) 2.61
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol (2000) 2.53
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry (2000) 2.25
Acute SSRI administration affects the processing of social cues in healthy volunteers. Neuropsychopharmacology (2003) 2.14
Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol (2008) 2.11
Chest pain: panic attack or heart attack? Int J Clin Pract (2000) 2.08
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
Consensus statement on posttraumatic stress disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry (2000) 1.87
Consensus statement on generalized anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry (2001) 1.86
Misuse of temazepam. BMJ (1991) 1.82
Equasy-- an overlooked addiction with implications for the current debate on drug harms. J Psychopharmacol (2009) 1.78
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol (2010) 1.74
Covariation of activity in habenula and dorsal raphé nuclei following tryptophan depletion. Neuroimage (1999) 1.65
Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease. Lancet (1990) 1.61
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
The effects of tryptophan depletion on cognitive and affective processing in healthy volunteers. Psychopharmacology (Berl) (2002) 1.56
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
Brain 5-HT neurotransmission during paroxetine treatment. Br J Psychiatry (1998) 1.48
Consensus statement on transcultural issues in depression and anxiety from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry (2001) 1.48
Fluoxetine and suicidal behaviour. Some clinical and theoretical aspects of a controversy. Br J Psychiatry (1992) 1.48
Successful treatment of night terrors and somnambulism with paroxetine. Br J Psychiatry (1994) 1.45
The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol (1999) 1.45
A web-based survey on mephedrone. Drug Alcohol Depend (2011) 1.45
Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry (2004) 1.45
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
A single dose of citalopram increases fear recognition in healthy subjects. J Psychopharmacol (2007) 1.43
Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry (1998) 1.42
The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. Mol Psychiatry (2012) 1.40
Brain 5-HT function in obsessive-compulsive disorder. Prolactin responses to d-fenfluramine. Br J Psychiatry (1997) 1.40
Abstinence symptoms after withdrawal of tranquillising drugs: is there a common neurochemical mechanism? Lancet (1982) 1.39
Evaluation of first night effect using ambulatory monitoring and automatic sleep stage analysis. Sleep (1988) 1.39
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
Panic response to lactate administration in alcoholic and nonalcoholic patients with panic disorder. Am J Psychiatry (1989) 1.38
'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci (1998) 1.37
Consensus statement on social anxiety disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry (1998) 1.36
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Oxytocin enhances processing of positive versus negative emotional information in healthy male volunteers. J Psychopharmacol (2008) 1.34
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
Abnormalities of sleep in patients with the chronic fatigue syndrome. BMJ (1993) 1.29
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
Tryptophan depletion decreases the recognition of fear in female volunteers. Psychopharmacology (Berl) (2003) 1.28
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
Tryptophan depletion in normal volunteers produces selective impairments in learning and memory. Neuropharmacology (1994) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
'It's not over when it's over': persistent neurobiological abnormalities in recovered depressed patients. Psychol Med (2008) 1.23
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23
Disturbances of hypothalamic-pituitary-adrenal axis functioning during ethanol withdrawal in six men. Am J Psychiatry (1991) 1.22
Changes in regional cerebral blood flow elicited by craving memories in abstinent opiate-dependent subjects. Am J Psychiatry (2001) 1.20
Evaluation of severe insomnia in the general population: results of a European multinational survey. J Psychopharmacol (1999) 1.19
A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17
Beyond psychoanaleptics - can we improve antidepressant drug nomenclature? J Psychopharmacol (2009) 1.16
The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
Seven genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis: a detailed analysis of gene networks and clinical phenotypes. J Clin Pathol (2007) 1.14
Slow wave sleep in humans: role of 5-HT2A and 5-HT2C receptors. Neuropharmacology (1994) 1.14
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12
Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. Psychopharmacology (Berl) (1999) 1.12
The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11
Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10
Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. Psychol Med (1976) 1.10
Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J (1979) 1.10
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10
Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10
Short-term SSRI treatment normalises amygdala hyperactivity in depressed patients. Psychol Med (2012) 1.09
Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev (2013) 1.08
Unusual interactions of benzodiazepine receptor antagonists. Nature (1982) 1.08
Tyrosine depletion attenuates dopamine function in healthy volunteers. Psychopharmacology (Berl) (2001) 1.08
The effects of chronic administration of hydrocortisone on cognitive function in normal male volunteers. Psychopharmacology (Berl) (1999) 1.07
Dieting reduces plasma tryptophan and alters brain 5-HT function in women. Psychol Med (1990) 1.07
The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. Br J Clin Pharmacol (1986) 1.07
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. Neuropharmacology (1976) 1.05
Studies on the post-ictal rise in seizure threshold. Eur J Pharmacol (1981) 1.05
Tryptophan hydroxylation in brain. Biochem Biophys Res Commun (1964) 1.04
Administration of the beta-adrenoceptor blocker propranolol impairs the processing of facial expressions of sadness. Psychopharmacology (Berl) (2001) 1.04
The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J (1972) 1.04
Evidence for the presence of a vasoactive substance (possibly involved in the aetiology of cerebral arterial spasm) in cerebrospinal fluid from patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (1976) 1.04